小牛血清联合鼠神经因子治疗小儿脑性瘫痪的临床观察

目的 探讨鼠神经因子联合小牛血清对小儿脑性瘫痪的临床疗效。方法 选取广元市妇幼保健院2015年1月-2017年6月收治的脑性瘫痪患儿60例，按治疗方法分为对照组、观察组，每组30例。对照组使用20 μg鼠神经生长因子注射液加2 mL灭菌注射用水溶解，肌肉注射，隔日1次，10 d为1疗程，间隔10 d，共3个疗程。观察组在对照组的基础上联合使用20 mL小牛血清去蛋白注射液加200~300 mL 5%葡萄糖，静脉滴注，每天1次，20 d为1疗程，间隔10 d，共2个疗程。比较两组患儿治疗前后发育商（DQ）评分的变化及临床疗效。结果 两组患儿治疗前的DQ评分无显著性差异；治疗后，两组患儿的DQ评分均显著提高，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组的DQ评分显著高于对照组，差异有统计学意义（P<0.05）。观察组临床疗效的总有效率（86.67%）显著高于对照组（73.33%），差异有统计学意义（P<0.05）。结论 鼠神经因子联合小牛血清对小儿脑性瘫痪的疗效较好，能提高患儿发育商评分，值得临床应用和推广。

Clinical observation of mouse nerve growth factor combined with calf serum in the treatment of pediatric cerebral palsy

Objective To explore the clinical efficacy of mouse nerve growth factor combined with calf serum in the treatment of pediatric cerebral palsy. Methods Selected 60 patients with cerebral palsy in our hospital from January 2015 to June 2017. All patients were divided into control group and observation group by treatment methods, each of group of 30 cases. The control group was treated with mouse nerve growth factor. The observation group was treated with calf serum on basis of control group. The clinical efficacy and development quotient scores were compared between the two groups. Results There was no significant difference between the two groups of development quotient scores before the treatment. The DQ scores of the two groups both improved after treatment (P<0.05). The DQ score in observation group was higher than that in control group after treatment (P<0.05). The effective rate of clinical efficacy in observation group (86.67%) was higher than that in control group (73.33%) (P<0.05). Conclusions The clinical efficacy of mouse nerve growth factor combined with calf serum in treatment of pediatric cerebral palsy is fine, safe and reliable, worthy of clinical application and promotion.